Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Key Emerging Trends in the Companion Diagnostic Market
To find out if certain medicines should be used to treat lung cancer, partner diagnostic tests, or CDXs, must be done. People with lung cancer have a better chance of living if they get partner tests as part of their first treatment. People around the world are getting more non-small cell lung cancer (NSCLC), and more oncology partner diagnostic tests are being made for the disease. This means that the group is likely to grow.
The US Food and Drug Administration (FDA) gave the Oncomine Dx Target Test from Thermo Fisher Scientific the all-clear before it came out in August 2022. Doctors can use this companion test (CDx) to find people with non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) activating mutations (SNVs & Exon 20 Insertion) and who may be good candidates for ENHERTU (fam-trastuzumab deruxtecan-nxki). ENTER is an ADC, which is an antibody made to fight HER2. It was made by Daiichi Sankyo and AstraZeneca together.
The most common type of cancer in this area is lung cancer. The Lung Cancer Research Foundation said in 2022 that 236,740 people in the US had been diagnosed with lung cancer. It takes more blood tests to find partners who have lung cancer because of this. The market is expected to get bigger over the next few years.
Because of these things, the market in the area is likely to keep growing over the next few years.
Custom drugs are becoming really interesting to people all over the world. A growing number of people around the world are being diagnosed with cancer. It's not true, according to the Australian Institute of Health and Welfare. Every day in December 2021, 413 people in Australia were told they had cancer, and 135 people died. More companies are working together to make tests and measurements better and cut costs. Many new uses have been found for it to help with brain issues, cancer, and heart disease.
It is safe to say that the above things are impacting the growth of the partner testing company. People think the market will grow, but it might take longer than they thought. This is because it costs a lot to make new medicines and, in many places, it's hard to get money for clinical research.
Companion Diagnostic Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
